

Dorothy K Hatsukami

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2925761/dorothy-k-hatsukami-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

301
papers

11,199
citations

57
h-index

92
g-index

318
ext. papers

12,924
ext. citations

5.2
avg, IF

6.15
L-index

#	Paper	IF	Citations
301	Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention.. <i>Nature Reviews Cancer</i> , 2022 ,	31.3	5
300	Balfour et al. Respond.. <i>American Journal of Public Health</i> , 2022 , 112, e2-e3	5.1	
299	Balfour et al. Respond.. <i>American Journal of Public Health</i> , 2022 , 112, e5-e6	5.1	
298	Urinary Nicotine Metabolites and Self-Reported Tobacco Use Among Adults in the Population Assessment of Tobacco and Health (PATH) Study, 2013-2014.. <i>Nicotine and Tobacco Research</i> , 2022 , 24, 768-777	4.9	1
297	The experimental tobacco marketplace: Effects of low-ventilated cigarette exposure. <i>Addictive Behaviors</i> , 2022 , 125, 107160	4.2	0
296	E-cigarette use and change in plans to quit cigarette smoking among adult smokers in the United States: Longitudinal findings from the PATH Study 2014-2019. <i>Addictive Behaviors</i> , 2022 , 124, 107124	4.2	1
295	The role of nicotine and flavor in the abuse potential and appeal of electronic cigarettes for adult current and former cigarette and electronic cigarette users: A systematic review.. <i>Nicotine and Tobacco Research</i> , 2022 ,	4.9	2
294	Response to: Appropriate policy implications of the fact that high content and flavored e-cigarettes have higher abuse liability.. <i>Nicotine and Tobacco Research</i> , 2022 ,	4.9	
293	Australian smokers' experiences and perceptions of recessed and firm filter cigarettes. <i>Tobacco Control</i> , 2021 , 30, 660-667	5.3	2
292	Association of e-Cigarette Use With Discontinuation of Cigarette Smoking Among Adult Smokers Who Were Initially Never Planning to Quit.. <i>JAMA Network Open</i> , 2021 , 4, e2140880	10.4	3
291	Serum Concentrations of Cotinine and Trans-3 β -Hydroxycotinine in US Adults: Results From Wave 1 (2013-2014) of the Population Assessment of Tobacco and Health Study.. <i>Nicotine and Tobacco Research</i> , 2021 ,	4.9	1
290	"I actually finally feel like the cigarettes aren't controlling me." - Interviews with participants smoking very low nicotine content cigarettes during a residential study. <i>Drug and Alcohol Dependence</i> , 2021 , 219, 108465	4.9	3
289	Cigarette smoking enhances the metabolic activation of the polycyclic aromatic hydrocarbon phenanthrene in humans. <i>Carcinogenesis</i> , 2021 , 42, 570-577	4.6	3
288	Menthol and Mint Cigarettes and Cigars: Initiation and Progression in Youth, Young Adults and Adults in Waves 1-4 of the PATH Study, 2013-2017. <i>Nicotine and Tobacco Research</i> , 2021 , 23, 1318-1326	4.9	6
287	Blunted opioid regulation of the HPA stress response during nicotine withdrawal: therapeutic implications. <i>Stress</i> , 2021 , 24, 529-540	3	5
286	Effects on time to lapse of switching menthol smokers to non-menthol cigarettes prior to a cessation attempt: a pilot study. <i>Tobacco Control</i> , 2021 , 30, 574-577	5.3	2
285	Urinary Cotinine and Cotinine + Trans-3 β -Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013-2014). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1175-1184	4	3

284	Risk Perceptions of Low Nicotine Cigarettes and Alternative Nicotine Products across Priority Smoking Populations. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
283	Effects on Smoking Behavior of Switching Menthol Smokers to Non-menthol Cigarettes. <i>Nicotine and Tobacco Research</i> , 2021 , 23, 1921-1927	4.9	2
282	3-Ethenylpyridine Measured in Urine of Active and Passive Smokers: A Promising Biomarker and Toxicological Implications. <i>Chemical Research in Toxicology</i> , 2021 , 34, 1630-1639	4	1
281	Regulatory approaches and implementation of minimally addictive combusted products. <i>Nicotine and Tobacco Research</i> , 2021 ,	4.9	1
280	A mixed effects model for analyzing area under the curve of longitudinally measured biomarkers with missing data. <i>Pharmaceutical Statistics</i> , 2021 , 20, 1249-1264	1	
279	Cigarette Smokers Versus Cannabis Smokers Versus Co-users of Cigarettes and Cannabis: A Pilot Study Examining Exposure to Toxicants. <i>Nicotine and Tobacco Research</i> , 2021 ,	4.9	2
278	Cardiovascular Risk Factor and Disease Measures from the Population Assessment of Tobacco and Health (PATH) Study. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
277	Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Users-Results from Wave 1 PATH Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1947-1955	4.9	2
276	Can the Public Be Educated About Constituents in Smokeless Tobacco? A Three-Wave Randomized Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2021 , 23, 161-170	4.9	1
275	Tobacco-Specific Nitrosamines (NNAL, NNN, NAT, and NAB) Exposures in the US Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014). <i>Nicotine and Tobacco Research</i> , 2021 , 23, 573-583	4.9	12
274	An Evaluation of Potential Unintended Consequences of a Nicotine Product Standard: A Focus on Drinking History and Outcomes. <i>Nicotine and Tobacco Research</i> , 2021 , 23, 1168-1175	4.9	3
273	Support for a nicotine reduction policy among participants enrolled in a 20-week trial of very low nicotine content cigarettes. <i>Addictive Behaviors</i> , 2021 , 114, 106727	4.2	0
272	Impact of Cigarette Filter Ventilation on U.S. Smokers' Perceptions and Biomarkers of Exposure and Potential Harm. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 38-44	4	5
271	Differences in exposure to toxic and/or carcinogenic volatile organic compounds between Black and White cigarette smokers. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2021 , 31, 211-223	6.7	8
270	Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder. <i>Nicotine and Tobacco Research</i> , 2021 ,	4.9	3
269	Early life adversity and appetite hormones: The effects of smoking status, nicotine withdrawal, and relapse on ghrelin and peptide YY during smoking cessation. <i>Addictive Behaviors</i> , 2021 , 118, 106866	4.2	0
268	Cigarette Filter Ventilation and Biomarkers-Reply. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1450	4	
267	Impact of nicotine reduction in cigarettes on smoking behavior and exposure: Are there differences by race/ethnicity, educational attainment, or gender?. <i>Drug and Alcohol Dependence</i> , 2021 , 225, 108756	4.9	1

266	Balancing Consideration of the Risks and Benefits of E-Cigarettes. <i>American Journal of Public Health</i> , 2021 , 111, 1661-1672	5.1	26
265	Recommendations to researchers for aiding in increasing American Indian representation in genetic research and personalized medicine. <i>Personalized Medicine</i> , 2021 , 18, 67-74	2.2	3
264	Applying Tobacco, Environmental, and Dietary-Related Biomarkers to Understand Cancer Etiology and Evaluate Prevention Strategies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1904-1914	4	2
263	The role of subjective responses in electronic cigarette uptake and substitution in adult smokers. <i>Drug and Alcohol Dependence</i> , 2020 , 212, 107999	4.9	3
262	Urinary Cyanoethyl Mercapturic Acid, a Biomarker of the Smoke Toxicant Acrylonitrile, Clearly Distinguishes Smokers From Nonsmokers. <i>Nicotine and Tobacco Research</i> , 2020 , 22, 1744-1747	4.9	7
261	Effects of 2-Phenethyl Isothiocyanate on Metabolism of 1,3-Butadiene in Smokers. <i>Cancer Prevention Research</i> , 2020 , 13, 91-100	3.2	5
260	Genotype Influences Serum Cotinine Levels and Is a Primary Determinant of Higher Cotinine in African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1673-1678	4	4
259	Reducing the relative value of cigarettes: Considerations for nicotine and non-nicotine factors. <i>Neuropharmacology</i> , 2020 , 175, 108200	5.5	4
258	Betel Quid, Health, and Addiction. <i>Substance Use and Misuse</i> , 2020 , 55, 1528-1532	2.2	3
257	Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings From Two Studies of U.S. Commercial Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 871-879	4	6
256	Chemical characterization of smokeless tobacco products and relevant exposures in users 2020 , 121-150		2
255	Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013-2014). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 659-667	4	12
254	Tobacco harm reduction: Past history, current controversies and a proposed approach for the future. <i>Preventive Medicine</i> , 2020 , 140, 106099	4.3	22
253	The Impact of Exclusive Use of Very Low Nicotine Cigarettes on Compensatory Smoking: An Inpatient Crossover Clinical Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 880-886	4	9
252	Analysis of Multiple Biomarkers Using Structural Equation Modeling.. <i>Tobacco Regulatory Science (discontinued)</i> , 2020 , 6, 266-278	2	
251	Cigarette Smokers Versus Cousers of Cannabis and Cigarettes: Exposure to Toxicants. <i>Nicotine and Tobacco Research</i> , 2020 , 22, 1383-1389	4.9	8
250	A Randomized Clinical Trial Examining the Effects of Instructions for Electronic Cigarette Use on Smoking-Related Behaviors and Biomarkers of Exposure. <i>Nicotine and Tobacco Research</i> , 2020 , 22, 1524-1532	4.9	28
249	Betel Nut (areca) and Smokeless Tobacco Use in Myanmar. <i>Substance Use and Misuse</i> , 2020 , 55, 1385-1394	4.2	9

248	Facilitating smoking cessation using reduced nicotine cigarettes: Intervention development and RCT study design. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106172	2.3	
247	High School Youth and E-cigarettes: The Influence of Modified Risk Statements and Flavors on E-cigarette Packaging. <i>American Journal of Health Behavior</i> , 2020 , 44, 130-145	1.9	5
246	Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16. <i>PLoS ONE</i> , 2020 , 15, e0237938	3.7	25
245	Mouth-Level Nicotine Intake Estimates from Discarded Filter Butts to Examine Compensatory Smoking in Low Nicotine Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 643-649	4	3
244	Smoking Topography Characteristics During a 6-Week Trial of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness. <i>Nicotine and Tobacco Research</i> , 2020 , 22, 1414-1418	4.9	9
243	Development and Piloting Testing of an Experimental Tobacco and Nicotine Product Marketplace. <i>Nicotine and Tobacco Research</i> , 2020 , 22, 1230-1234	4.9	1
242	A Randomized Clinical Trial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure. <i>Nicotine and Tobacco Research</i> , 2020 , 22, 473-481	4.9	2
241	The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers. <i>Cancer Prevention Research</i> , 2020 , 13, 483-492	3.2	4
240	Randomized Trial of Low-Nicotine Cigarettes and Transdermal Nicotine. <i>American Journal of Preventive Medicine</i> , 2019 , 57, 515-524	6.1	15
239	Strategies to Reduce Illicit Trade of Regular Nicotine Tobacco Products After Introduction of a Low-Nicotine Tobacco Product Standard. <i>American Journal of Public Health</i> , 2019 , 109, 1007-1014	5.1	12
238	Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects. <i>Addiction</i> , 2019 , 114, 1824-1833	4.6	3
237	Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. <i>PLoS ONE</i> , 2019 , 14, e0215853	3.7	7
236	Smokeless tobacco control in 180 countries across the globe: call to action for full implementation of WHO FCTC measures. <i>Lancet Oncology, The</i> , 2019 , 20, e208-e217	21.7	38
235	Biomarkers of Exposure among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 943-953	4.5	21
234	Effects of cessation of cigarette smoking on eicosanoid biomarkers of inflammation and oxidative damage. <i>PLoS ONE</i> , 2019 , 14, e0218386	3.7	11
233	Smokeless tobacco, snus, at admission for percutaneous coronary intervention and future risk for cardiac events. <i>Open Heart</i> , 2019 , 6, e001109	3	0
232	Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers. <i>Nicotine and Tobacco Research</i> , 2019 , 21, S63-S72	4.9	11
231	The Impact of Gradual and Immediate Nicotine Reduction on Subjective Cigarette Ratings. <i>Nicotine and Tobacco Research</i> , 2019 , 21, S73-S80	4.9	11

230	The Role of Compensation in Nicotine Reduction. <i>Nicotine and Tobacco Research</i> , 2019 , 21, S16-S18	4.9	5
229	Effects of 6-Week Use of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness. <i>Nicotine and Tobacco Research</i> , 2019 , 21, S38-S45	4.9	22
228	Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes. <i>Tobacco Control</i> , 2019 , 28, 352-355	5.3	4
227	Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein. <i>PLoS ONE</i> , 2019 , 14, e0210104	3.7	13
226	The Debate About Nicotine Addiction and the Role of Medicinal Products: Commentary on Zeller. <i>Nicotine and Tobacco Research</i> , 2019 , 21, 338-339	4.9	4
225	Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop. <i>Nicotine and Tobacco Research</i> , 2019 , 21, 3-13	4.9	20
224	Age Moderates Smokers' Subjective Response to Very-Low Nicotine Content Cigarettes: Evidence from a Randomized Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2019 , 21, 962-969	4.9	19
223	Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus. <i>Nicotine and Tobacco Research</i> , 2018 , 20, 1292-1300	4.9	7
222	Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health. <i>Preventive Medicine</i> , 2018 , 117, 8-14	4.3	18
221	CYP2A6 metabolism in the development of smoking behaviors in young adults. <i>Addiction Biology</i> , 2018 , 23, 437-447	4.6	7
220	Perceived risks and reasons to smoke cigarettes during pregnancy among Alaska native women. <i>Ethnicity and Health</i> , 2018 , 23, 33-42	2.2	4
219	Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco. <i>Tobacco Control</i> , 2018 , 27, 352-354	5.3	7
218	Effects of Filter Ventilation on Behavioral Economic Demand for Cigarettes: A Preliminary Investigation. <i>Nicotine and Tobacco Research</i> , 2018 , 20, 1278-1282	4.9	4
217	Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks. <i>Tobacco Control</i> , 2018 , 27, 420-426	5.3	17
216	Hormonal contraceptive use in smokers: Prevalence of use and associations with smoking motives. <i>Addictive Behaviors</i> , 2018 , 77, 187-192	4.2	8
215	Use of hormonal contraceptives and smoking cessation: A preliminary report. <i>Addictive Behaviors</i> , 2018 , 76, 236-242	4.2	7
214	Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers. <i>Npj Precision Oncology</i> , 2018 , 2, 17	9.8	25
213	Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence. <i>Experimental and Clinical Psychopharmacology</i> , 2018 , 26, 223-232	3.2	8

212	Cigarette and e-liquid demand and substitution in e-cigarette-naïve smokers. <i>Experimental and Clinical Psychopharmacology</i> , 2018 , 26, 233-243	3.2	16
211	Evaluating the utility of subjective effects measures for predicting product sampling, enrollment, and retention in a clinical trial of a smokeless tobacco product. <i>Addictive Behaviors</i> , 2018 , 76, 95-99	4.2	6
210	Assessing the Impact of Conflicting Health Warning Information on Intentions to Use E-Cigarettes -An Application of the Heuristic-Systematic Model. <i>Journal of Health Communication</i> , 2018 , 23, 874-885	2.5	10
209	Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. <i>JAMA Network Open</i> , 2018 , 1, e185937	10.4	224
208	Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 880-891	27.4	76
207	Adolescent smokers' response to reducing the nicotine content of cigarettes: Acute effects on withdrawal symptoms and subjective evaluations. <i>Drug and Alcohol Dependence</i> , 2018 , 188, 153-160	4.9	17
206	Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms. <i>Addictive Behaviors</i> , 2017 , 71, 18-24	4.2	12
205	Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1093-1099	4	16
204	Reducing the nicotine content of combusted tobacco products sold in New Zealand. <i>Tobacco Control</i> , 2017 , 26, e37-e42	5.3	13
203	Internalized smoking stigma in relation to quit intentions, quit attempts, and current e-cigarette use. <i>Substance Abuse</i> , 2017 , 38, 330-336	3.8	9
202	Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	46
201	Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes. <i>Tobacco Control</i> , 2017 , 26, e43-e48	5.3	13
200	Sex differences in physiological response to the combination of stress and smoking. <i>International Journal of Psychophysiology</i> , 2017 , 118, 27-31	2.9	8
199	Cigarette Nicotine Content as a Moderator of the Relationship Between Negative Affect and Smoking. <i>Nicotine and Tobacco Research</i> , 2017 , 19, 1080-1086	4.9	8
198	The case for the WHO Advisory Note, Global Nicotine Reduction Strategy. <i>Tobacco Control</i> , 2017 , 26, e29-e30	5.3	6
197	Isotope Dilution nanoLC/ESI-HRMS Quantitation of Urinary N7-(1-Hydroxy-3-buten-2-yl) Guanine Adducts in Humans and Their Use as Biomarkers of Exposure to 1,3-Butadiene. <i>Chemical Research in Toxicology</i> , 2017 , 30, 678-688	4	14
196	Tobacco Product Use Patterns, and Nicotine and Tobacco-Specific Nitrosamine Exposure: NHANES 1999-2012. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1525-1530	4	19
195	Strong preference for mint snus flavor among research participants. <i>Addictive Behaviors Reports</i> , 2017 , 6, 51-55	3.7	3

194	High Level of Tobacco Carcinogen-Derived DNA Damage in Oral Cells Is an Independent Predictor of Oral/Head and Neck Cancer Risk in Smokers. <i>Cancer Prevention Research</i> , 2017 , 10, 507-513	3.2	21
193	Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: further results from a multi-site clinical trial. <i>Addiction</i> , 2017 , 112, 349-359	4.6	37
192	Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms. <i>Nicotine and Tobacco Research</i> , 2017 , 19, 59-67	4.9	40
191	Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial. <i>Addiction</i> , 2017 , 112, 156-167	4.6	29
190	Evaluation of modified risk claim advertising formats for Camel Snus. <i>Health Education Journal</i> , 2017 , 76, 971-985	1.5	14
189	Constituent Variations in Smokeless Tobacco Purchased in Mumbai, India. <i>Tobacco Regulatory Science (discontinued)</i> , 2017 , 3, 305-314	2	5
188	E-cigarettes Warning Labels and Modified Risk Statements: Tests of Messages to Reduce Recreational Use. <i>Tobacco Regulatory Science (discontinued)</i> , 2017 , 3, 445-458	2	17
187	Psychometric Characteristics of the Brief Wisconsin Inventory of Smoking Dependence Motives Among a Nonclinical Sample of Smokers. <i>Nicotine and Tobacco Research</i> , 2016 , 18, 470-6	4.9	6
186	Validation of a Measure of Normative Beliefs About Smokeless Tobacco Use. <i>Nicotine and Tobacco Research</i> , 2016 , 18, 801-8	4.9	6
185	Optimized Liquid Chromatography Nanoelectrospray-High-Resolution Tandem Mass Spectrometry Method for the Analysis of 4-Hydroxy-1-(3-pyridyl)-1-butanone-Releasing DNA Adducts in Human Oral Cells. <i>Chemical Research in Toxicology</i> , 2016 , 29, 1849-1856	4	18
184	The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use. <i>Alcoholism: Clinical and Experimental Research</i> , 2016 , 40, 606-15	3.7	15
183	Call to Establish Constituent Standards for Smokeless Tobacco Products. <i>Tobacco Regulatory Science (discontinued)</i> , 2016 , 2, 9-30	2	12
182	Perceived Health Risks of Snus and Medicinal Nicotine Products. <i>Nicotine and Tobacco Research</i> , 2016 , 18, 794-800	4.9	16
181	Gender Differences in Smoking Behavior and Dependence Motives Among Daily and Nondaily Smokers. <i>Nicotine and Tobacco Research</i> , 2016 , 18, 1408-13	4.9	30
180	Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching. <i>Tobacco Control</i> , 2016 , 25, 267-74	5.3	25
179	Quantitation of the Minor Tobacco Alkaloids Nor nicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2016 , 29, 390-7	4	24
178	Preference for Flavored Noncombustible Nicotine Products Among Smokers Motivated to Switch From Cigarettes. <i>Nicotine and Tobacco Research</i> , 2016 , 18, 892-3	4.9	8
177	Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers. <i>Cancer Prevention Research</i> , 2016 , 9, 396-405	3.2	44

176	Application of the Smokeless Tobacco Expectancies Questionnaire to Snus. <i>American Journal of Health Behavior</i> , 2016 , 40, 652-8	1.9	4
175	Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes. <i>Tobacco Regulatory Science (discontinued)</i> , 2016 , 2, 186-203	2	23
174	Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. <i>Addiction</i> , 2016 , 111, 2208-2216	4.6	37
173	Persistence and amplitude of cigarette demand in relation to quit intentions and attempts. <i>Psychopharmacology</i> , 2016 , 233, 2365-71	4.7	35
172	Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings. <i>Nicotine and Tobacco Research</i> , 2016 , 18, 2162-2168	4.9	7
171	2-Phenethyl Isothiocyanate, Glutathione S-transferase M1 and T1 Polymorphisms, and Detoxification of Volatile Organic Carcinogens and Toxicants in Tobacco Smoke. <i>Cancer Prevention Research</i> , 2016 , 9, 598-606	3.2	19
170	Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use. <i>Drug and Alcohol Dependence</i> , 2016 , 167, 228-32	4.9	16
169	Gender differences in snus versus nicotine gum for cigarette avoidance among a sample of US smokers. <i>Drug and Alcohol Dependence</i> , 2016 , 168, 8-12	4.9	2
168	Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. <i>EBioMedicine</i> , 2016 , 11, 219-226	8.8	27
167	A review of the additive health risk of cannabis and tobacco co-use. <i>Drug and Alcohol Dependence</i> , 2016 , 166, 6-12	4.9	92
166	Biochemical estimation of noncompliance with smoking of very low nicotine content cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 331-5	4	19
165	Circulating leptin and pain perception among tobacco-dependent individuals. <i>Biological Psychology</i> , 2015 , 107, 10-5	3.2	5
164	CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	55
163	Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 472-6	4	41
162	Sex differences in hormonal responses to stress and smoking relapse: a prospective examination. <i>Nicotine and Tobacco Research</i> , 2015 , 17, 382-9	4.9	43
161	Randomized Trial of Reduced-Nicotine Standards for Cigarettes. <i>New England Journal of Medicine</i> , 2015 , 373, 1340-9	59.2	237
160	Assessing Constituent Levels in Smokeless Tobacco Products: A New Approach to Engaging and Educating the Public. <i>Nicotine and Tobacco Research</i> , 2015 , 17, 1354-61	4.9	11
159	NIH electronic cigarette workshop: developing a research agenda. <i>Nicotine and Tobacco Research</i> , 2015 , 17, 259-69	4.9	80

158	Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. <i>Nicotine and Tobacco Research</i> , 2015 , 17, 704-9	4.9	162
157	The effect of combination oral contraceptives on smoking-related symptomatology during short-term smoking abstinence. <i>Addictive Behaviors</i> , 2015 , 41, 148-51	4.2	9
156	Providing a Science Base for the Evaluation of Tobacco Products. <i>Tobacco Regulatory Science (discontinued)</i> , 2015 , 1, 76-93	2	32
155	Evidence supporting product standards for carcinogens in smokeless tobacco products. <i>Cancer Prevention Research</i> , 2015 , 8, 20-6	3.2	26
154	Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking. <i>Chemical Research in Toxicology</i> , 2015 , 28, 2390-9	4	16
153	High levels of tobacco-specific N-nitrosamines and nicotine in Chaini Khaini, a product marketed as snus. <i>Tobacco Control</i> , 2015 , 24, e271-4	5.3	21
152	Greater reductions in nicotine exposure while smoking very low nicotine content cigarettes predict smoking cessation. <i>Tobacco Control</i> , 2015 , 24, 536-9	5.3	19
151	Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. <i>Clinical Cancer Research</i> , 2015 , 21, 514-25	12.9	58
150	Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. <i>Drug and Alcohol Dependence</i> , 2015 , 154, 278-82	4.9	30
149	Subjective response to nicotine by menstrual phase. <i>Addictive Behaviors</i> , 2015 , 43, 50-3	4.2	13
148	Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015 , 33, 952-63	2.2	80
147	Smoker Response to a Simulated Ban of Menthol Cigarettes: A Pilot Study. <i>Tobacco Regulatory Science (discontinued)</i> , 2015 , 1, 236-242	2	3
146	A Pilot Product Preference Study of Electronic Cigarettes and Nicotine Gum as Potential Smoking Cessation Aids for African-American Menthol Smokers. <i>Tobacco Regulatory Science (discontinued)</i> , 2015 , 1, 243-253	2	2
145	Women and Smoking: The Effect of Gender on the Epidemiology, Health Effects, and Cessation of Smoking. <i>Current Addiction Reports</i> , 2014 , 1, 53-60	3.9	74
144	Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). <i>Addiction</i> , 2014 , 109, 128-137	4.6	59
143	Public education about the relative harm of tobacco products: an intervention for tobacco control professionals. <i>Tobacco Control</i> , 2014 , 23, 385-8	5.3	26
142	Monitoring tobacco-specific N-nitrosamines and nicotine in novel smokeless tobacco products: findings from round II of the new product watch. <i>Nicotine and Tobacco Research</i> , 2014 , 16, 1070-8	4.9	26
141	Nicotine reduction as an increase in the unit price of cigarettes: a behavioral economics approach. <i>Preventive Medicine</i> , 2014 , 68, 23-8	4.3	17

140	Reduced nicotine product standards for combustible tobacco: building an empirical basis for effective regulation. <i>Preventive Medicine</i> , 2014 , 68, 17-22	4.3	50
139	Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 155-63	27.4	87
138	Smoking- and menstrual-related symptomatology during short-term smoking abstinence by menstrual phase and depressive symptoms. <i>Addictive Behaviors</i> , 2014 , 39, 901-6	4.2	18
137	Sex differences in response to reduced nicotine content cigarettes. <i>Addictive Behaviors</i> , 2014 , 39, 1197-204	4.4	24
136	Analysis of 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB)-releasing DNA adducts in human exfoliated oral mucosa cells by liquid chromatography-electrospray ionization-tandem mass spectrometry. <i>Chemical Research in Toxicology</i> , 2013 , 26, 37-45	4	33
135	Reduced nicotine content cigarettes and nicotine patch. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1015-24	4	52
134	Dose-response effects of spectrum research cigarettes. <i>Nicotine and Tobacco Research</i> , 2013 , 15, 1113-24	4.9	61
133	Menstrual phase, depressive symptoms, and allopregnanolone during short-term smoking cessation. <i>Experimental and Clinical Psychopharmacology</i> , 2013 , 21, 427-33	3.2	10
132	Subjective responses to oral tobacco products: scale validation. <i>Nicotine and Tobacco Research</i> , 2013 , 15, 1259-64	4.9	31
131	Nornicotine nitrosation in saliva and its relation to endogenous synthesis of N-nitrosornicotine in humans. <i>Nicotine and Tobacco Research</i> , 2013 , 15, 591-5	4.9	27
130	Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects. <i>Nicotine and Tobacco Research</i> , 2013 , 15, 88-92	4.9	38
129	Menstrual phase and depressive symptoms differences in physiological response to nicotine following acute smoking abstinence. <i>Nicotine and Tobacco Research</i> , 2013 , 15, 1091-8	4.9	15
128	Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. <i>Carcinogenesis</i> , 2013 , 34, 93-101	4.6	34
127	Nicotine reduction: strategic research plan. <i>Nicotine and Tobacco Research</i> , 2013 , 15, 1003-13	4.9	52
126	The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 708-18	4	62
125	Ending tobacco-caused mortality and morbidity: the case for performance standards for tobacco products. <i>Tobacco Control</i> , 2013 , 22 Suppl 1, i36-7	5.3	8
124	Kinetics of DNA adduct formation in the oral cavity after drinking alcohol. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 601-8	4	55
123	Nicotine vaccines for smoking cessation. <i>The Cochrane Library</i> , 2012 , CD007072	5.2	50

122	Very low nicotine content cigarettes and potential consequences on cardiovascular disease. <i>Current Cardiovascular Risk Reports</i> , 2012 , 6, 534-541	0.9	2
121	Increased pouch sizes and resulting changes in the amounts of nicotine and tobacco-specific N-nitrosamines in single pouches of Camel Snus and Marlboro Snus. <i>Nicotine and Tobacco Research</i> , 2012 , 14, 1241-5	4.9	16
120	Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch. <i>Nicotine and Tobacco Research</i> , 2012 , 14, 274-81	4.9	37
119	Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation. <i>Nicotine and Tobacco Research</i> , 2012 , 14, 902-9	4.9	8
118	Tobacco and nicotine product testing. <i>Nicotine and Tobacco Research</i> , 2012 , 14, 7-17	4.9	23
117	Exposure to nicotine and carcinogens among Southwestern Alaskan Native cigarette smokers and smokeless tobacco users. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 934-42	4	27
116	Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. <i>Drug and Alcohol Dependence</i> , 2011 , 116, 1-7	4.9	35
115	Oral tobacco products: preference and effects among smokers. <i>Drug and Alcohol Dependence</i> , 2011 , 118, 230-6	4.9	25
114	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers. <i>Biomarkers</i> , 2011 , 16, 491-7	2.6	23
113	Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 91-100	4	31
112	Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. <i>Addiction</i> , 2010 , 105, 343-55	4.6	177
111	Commentary on Post et al. (2010): Snus, a cautionary reminder. <i>Addiction</i> , 2010 , 105, 747-8	4.6	1
110	Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1389-98	4	41
109	Nicotine reduction revisited: science and future directions. <i>Tobacco Control</i> , 2010 , 19, e1-10	5.3	75
108	Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 332, 202-9	4.7	49
107	Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention. <i>Nicotine and Tobacco Research</i> , 2010 , 12, 823-7	4.9	13
106	UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1423-31	4	27
105	Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. <i>Chemical Research in Toxicology</i> , 2010 , 23, 1001-8	4	82

104	Analysis of 23 polycyclic aromatic hydrocarbons in smokeless tobacco by gas chromatography-mass spectrometry. <i>Chemical Research in Toxicology</i> , 2010 , 23, 66-73	4	63
103	Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3305-20	4	74
102	Transdisciplinary Tobacco Use Research Centers: research achievements and future implications. <i>Nicotine and Tobacco Research</i> , 2009 , 11, 1231-44	4.9	2
101	Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3225-40	4	40
100	Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3334-48	4	20
99	Abuse liability assessment of tobacco products including potential reduced exposure products. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3241-62	4	117
98	Methods used in internal industry clinical trials to assess tobacco risk reduction. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3196-208	4	8
97	The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. <i>Tobacco Control</i> , 2009 , 18, 324-32	5.3	147
96	Measures for assessing subjective effects of potential reduced-exposure products. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3209-24	4	16
95	Presence of the carcinogen NQnitrosornicotine in the urine of some users of oral nicotine replacement therapy products. <i>Cancer Research</i> , 2009 , 69, 8236-40	10.1	51
94	Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009 , 150B, 453-66	3.5	173
93	Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. <i>Chemical Research in Toxicology</i> , 2009 , 22, 734-41	4	141
92	Nicotine withdrawal and craving in adolescents: effects of sex and hormonal contraceptive use. <i>Addictive Behaviors</i> , 2009 , 34, 620-3	4.2	29
91	A testable prognostic model of nicotine dependence. <i>Journal of Neurogenetics</i> , 2009 , 23, 283-92	1.6	12
90	Clinical trials methods for evaluation of potential reduced exposure products. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3143-95	4	30
89	Menstrual phase effects on smoking relapse. <i>Addiction</i> , 2008 , 103, 809-21	4.6	100
88	Detecting longitudinal patterns of daily smoking following drastic cigarette reduction. <i>Addictive Behaviors</i> , 2008 , 33, 623-39	4.2	26
87	Tobacco addiction. <i>Lancet, The</i> , 2008 , 371, 2027-38	40	166

86	Smokeless tobacco for cigarette cessation? Authors Reply. <i>Lancet, The</i> , 2008 , 372, 1217	4.0	
85	New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. <i>Nicotine and Tobacco Research</i> , 2008 , 10, 1773-82	4.9	195
84	Smokeless tobacco reduction: preliminary study of tobacco-free snuff versus no snuff. <i>Nicotine and Tobacco Research</i> , 2008 , 10, 77-85	4.9	13
83	Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial. <i>Nicotine and Tobacco Research</i> , 2008 , 10, 471-81	4.9	37
82	Nicotine vaccines for smoking cessation 2008 ,		4
81	Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking. <i>Chemical Research in Toxicology</i> , 2007 , 20, 986-90	4	119
80	Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation. <i>Chemical Research in Toxicology</i> , 2007 , 20, 108-13	4	62
79	Effects of high dose transdermal nicotine replacement in cigarette smokers. <i>Pharmacology Biochemistry and Behavior</i> , 2007 , 86, 132-9	3.9	38
78	Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. <i>Human Molecular Genetics</i> , 2007 , 16, 36-49	5.6	710
77	Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. <i>Tobacco Control</i> , 2007 , 16, 138-42	5.3	38
76	Developing the science base for reducing tobacco harm. <i>Nicotine and Tobacco Research</i> , 2007 , 9 Suppl 4, S537-53	4.9	43
75	Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. <i>Nicotine and Tobacco Research</i> , 2007 , 9 Suppl 4, S555-70	4.9	380
74	Perceived risk of harm from cigarettes or smokeless tobacco among U.S. high school seniors. <i>Nicotine and Tobacco Research</i> , 2007 , 9, 1191-6	4.9	31
73	Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1567-72	4	87
72	Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. <i>Nicotine and Tobacco Research</i> , 2007 , 9, 1309-23	4.9	31
71	Changing smokeless tobacco products new tobacco-delivery systems. <i>American Journal of Preventive Medicine</i> , 2007 , 33, S368-78	6.1	84
70	Attitudes and knowledge about nicotine and nicotine replacement therapy. <i>Nicotine and Tobacco Research</i> , 2006 , 8, 435-46	4.9	69
69	Tobacco-specific nitrosamines in new tobacco products. <i>Nicotine and Tobacco Research</i> , 2006 , 8, 309-13	4.9	113

68	Biomarkers to assess the utility of potential reduced exposure tobacco products. <i>Nicotine and Tobacco Research</i> , 2006 , 8, 600-22	4.9	66
67	Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1805-11	4	42
66	Toxicant exposure in cigarette reducers versus light smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 2355-8	4	35
65	Biomarkers to assess the utility of potential reduced exposure tobacco products. <i>Nicotine and Tobacco Research</i> , 2006 , 8, 169-91	4.9	48
64	Immunological Approaches to Nicotine Addiction 2006 , 151-166		
63	Effects of cigarette reduction on cardiovascular risk factors and subjective measures. <i>Chest</i> , 2005 , 128, 2528-37	5.3	64
62	Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 456-67	6.1	136
61	Smokeless tobacco topography and toxin exposure. <i>Nicotine and Tobacco Research</i> , 2005 , 7, 469-74	4.9	16
60	Interventions to increase use of nicotine gum: a randomized, controlled, single-blind trial. <i>Nicotine and Tobacco Research</i> , 2005 , 7, 565-79	4.9	38
59	Longitudinal study of urinary phenanthrene metabolite ratios: effect of smoking on the diol epoxide pathway. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 2969-74	4	41
58	Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 2963-8	4	100
57	Methods to assess potential reduced exposure products. <i>Nicotine and Tobacco Research</i> , 2005 , 7, 827-44	4.9	44
56	Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 693-8	4	107
55	Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 107-15	9.7	83
54	Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 844-52	9.7	95
53	Harm reduction approaches to reducing tobacco-related mortality. <i>Annual Review of Public Health</i> , 2004 , 25, 377-95	20.6	64
52	Smokeless tobacco use: harm reduction or induction approach?. <i>Preventive Medicine</i> , 2004 , 38, 309-17	4.3	120
51	Characteristics of cigarette smokers seeking treatment for cessation versus reduction. <i>Addictive Behaviors</i> , 2004 , 29, 357-64	4.2	16

50	Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. <i>American Journal of Medicine</i> , 2004 , 116, 151-7	2.4	41
49	Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 834-42	4	18
48	A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 1617-23	4	25
47	Transdisciplinary science applied to the evaluation of treatments for tobacco use. <i>Nicotine and Tobacco Research</i> , 2003 , 5 Suppl 1, S89-99	4.9	11
46	Treatment of adolescent smokers with the nicotine patch. <i>Nicotine and Tobacco Research</i> , 2003 , 5, 515-526	4.9	73
45	Lack of effect of 5HT3 antagonist in mediating subjective and behavioral responses to cotinine. <i>Pharmacology Biochemistry and Behavior</i> , 2003 , 75, 1-7	3.9	11
44	Efficacy of Nicotine Patch in Smokers With a History of Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 2003 , 27, 946-954	3.7	51
43	Preliminary study on reducing oral moist snuff use. <i>Drug and Alcohol Dependence</i> , 2003 , 70, 215-20	4.9	10
42	Effectiveness of over-the-counter nicotine replacement therapy. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 3109-10; author reply 3110	27.4	8
41	Reducing tobacco harm: research challenges and issues. <i>Nicotine and Tobacco Research</i> , 2002 , 4 Suppl 2, S89-101	4.9	53
40	Effective tobacco dependence treatment. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 1768-71	27.4	68
39	Ethylation and methylation of hemoglobin in smokers and non-smokers. <i>Carcinogenesis</i> , 2002 , 23, 1903-106	4.9	33
38	Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. <i>Cancer Research</i> , 2002 , 62, 129-34	10.1	39
37	Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002 , 11, 1668-73	4	55
36	Effect of nonnicotine pharmacotherapy on smoking behavior. <i>Pharmacotherapy</i> , 2001 , 21, 1530-48	5.8	21
35	Introduction: Tobacco treatment outcome methodology papers - a series. <i>Nicotine and Tobacco Research</i> , 2001 , 3, 191	4.9	18
34	Treatment of spit tobacco users with transdermal nicotine system and mint snuff.. <i>Journal of Consulting and Clinical Psychology</i> , 2000 , 68, 241-249	6.5	48
33	Individual differences in the subjective response to smoked cocaine in humans. <i>American Journal of Drug and Alcohol Abuse</i> , 2000 , 26, 591-602	3.7	15

32	Oral spit tobacco: addiction, prevention and treatment. <i>Nicotine and Tobacco Research</i> , 1999 , 1, 21-44	4.9	84
31	Withdrawal and pre-menstrual symptomatology during the menstrual cycle in short-term smoking abstinence: effects of menstrual cycle on smoking abstinence. <i>Nicotine and Tobacco Research</i> , 1999 , 1, 129-42	4.9	57
30	Pharmacological and Behavioral Strategies for Smoking Cessation. <i>Journal of Clinical Psychology in Medical Settings</i> , 1999 , 6, 11-38	2	8
29	Gender differences in the pharmacology of nicotine addiction. <i>Addiction Biology</i> , 1998 , 3, 383-404	4.6	81
28	Comparing IV and Non-IV Cocaine Users: Characteristics of a Sample of Cocaine Users Seeking to Participate in Research. <i>American Journal on Addictions</i> , 1998 , 7, 262-271	3.7	6
27	Effects of dynorphin A(1-13) on opiate withdrawal in humans. <i>Psychopharmacology</i> , 1998 , 137, 326-32	4.7	30
26	Variation in human plasma cholinesterase activity during low-dose cocaine administration. <i>Journal of Toxicology: Clinical Toxicology</i> , 1998 , 36, 3-9		6
25	The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. <i>Vascular Medicine</i> , 1997 , 2, 243-51	3.3	83
24	Safety of cotinine in humans: physiologic, subjective, and cognitive effects. <i>Pharmacology Biochemistry and Behavior</i> , 1997 , 57, 643-50	3.9	57
23	Effects of behavioral and pharmacological treatment on smokeless tobacco users.. <i>Journal of Consulting and Clinical Psychology</i> , 1996 , 64, 153-161	6.5	65
22	Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. <i>Psychopharmacology</i> , 1996 , 128, 130-8	4.7	129
21	Effects of short-term use of nicotine gum in pregnant smokers. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 654-61	6.1	54
20	Gender and the effects of different doses of nicotine gum on tobacco withdrawal symptoms.. <i>Experimental and Clinical Psychopharmacology</i> , 1995 , 3, 163-173	3.2	59
19	Pharmacodynamic effects of cotinine in abstinent cigarette smokers. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 581-90	6.1	46
18	Physical dependence on nicotine gum: effect of duration of use. <i>Psychopharmacology</i> , 1993 , 111, 449-564.7		24
17	Smokeless tobacco abstinence effects and nicotine gum dose. <i>Psychopharmacology</i> , 1992 , 106, 60-6	4.7	30
16	Smokeless tobacco: current status and future directions. <i>Addiction</i> , 1991 , 86, 559-63	4.6	11
15	Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users. <i>Psychopharmacology</i> , 1991 , 104, 120-4	4.7	34

14	Signs and symptoms from nicotine gum abstinence. <i>Psychopharmacology</i> , 1991 , 104, 496-504	4.7	12
13	Situational factors and patterns associated with smokeless tobacco use. <i>Journal of Behavioral Medicine</i> , 1991 , 14, 383-96	3.6	14
12	Effects of nicotine gum on prevalence and severity of withdrawal in female cigarette smokers. <i>Journal of Substance Abuse</i> , 1991 , 3, 427-40		20
11	A 25 year follow-up study of patients treated for bulimia. <i>International Journal of Eating Disorders</i> , 1989 , 8, 157-165	6.3	51
10	The impact of treatment on meal patterns in patients with bulimia nervosa. <i>International Journal of Eating Disorders</i> , 1989 , 8, 167-172	6.3	7
9	The effects of short-term smokeless tobacco deprivation on performance. <i>Psychopharmacology</i> , 1989 , 98, 126-30	4.7	40
8	Patients versus symptomatic volunteers in bulimia nervosa research. <i>International Journal of Eating Disorders</i> , 1988 , 7, 837-843	6.3	13
7	Symptoms of tobacco withdrawal from total cigarette cessation versus partial cigarette reduction. <i>Psychopharmacology</i> , 1988 , 94, 242-7	4.7	45
6	Metabolic acidosis as a marker for laxative abuse in patients with bulimia. <i>International Journal of Eating Disorders</i> , 1987 , 6, 557-560	6.3	14
5	Physiologic and subjective changes from smokeless tobacco withdrawal. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 103-7	6.1	71
4	Effect of nicotine on the tobacco withdrawal syndrome. <i>Psychopharmacology</i> , 1984 , 83, 82-7	4.7	244
3	Tobacco withdrawal symptoms: an experimental analysis. <i>Psychopharmacology</i> , 1984 , 84, 231-6	4.7	198
2	Affective disorder and substance abuse in women with bulimia. <i>Psychological Medicine</i> , 1984 , 14, 701-4	6.9	92
1	Electrolyte and other physiological abnormalities in patients with bulimia. <i>Psychological Medicine</i> , 1983 , 13, 273-8	6.9	101